PDF
NextCell Pharma AB: NextCell's cell therapy manufacturing experience highlighted at BIO-Europe 2026
NextCell Pharma AB announces that its Chief Scientific Officer, Dr Lindsay Davies, has been invited to present at BIO-Europe 2026 in Cologne, Germany. Her presentation will address the challenges of taking allogeneic cell therapies from clinical development to commercial production. The conference programme specifically highlights NextCell's experience in developing manufacturing processes for commercial production.
BIO-Europe, taking place on 9-11 November, is Europe's largest partnering conference for the biotechnology and pharmaceutical industries. The event brings together companies and investors from around the world to establish partnerships and explore new business opportunities.
On 10 November, Lindsay Davies will deliver her presentation on the conference's Biomanufacturing Strategy Stage, entitled Future-proofing Manufacturing for Commercialization of Allogeneic Cell Therapies: From Phase II to Global Commercialization. She will address key considerations for commercial production, including scale-up, technology transfer, process validation and regulatory requirements.
The presentation draws on NextCell's experience in manufacturing, process development and quality control gained through the development of its NXTCL cell therapy platform.
Lindsay Davies is also Vice President-Elect for Europe at the International Society for Cell & Gene Therapy (ISCT).
Read more about Lindsay's participation at BIO-Europe 2026: https://informaconnect.com/bioeurope/speakers/lindsay-davies/